KBI Biopharma is a U.S.-based subsidiary of the JSR Corporation. Through a strategic partnership with Selexis SA, KBI offers mammalian cell line development within nine months, the fastest service offering in the biopharmaceutical industry. KBI specializes in clinical and commercial manufacturing services for mammalian, microbial, and cell therapy programs. KBI has completed thousands of projects, and in mammalian projects alone, they have completed over 190 programs and supported over 15 annual INDs.
Visit Company Website
